We are studying reappearence of nondepolarizing neuromuscular block after it has been antagonized with a combination of neostigmine and glycopyrrolate. We are trying to find the incidence of the phenomenon.
Conditions
Interventions
Trade Name: Glycostigmin
Product Name: Glycostigmin
Pharmaceutical Form: Injection
Sponsors
Tampere University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: AGE 18-65 years ASA risk class 1-2 Elective surgery reguiring general anaesthesia with estimated duration over 45 min. Body Mass Index (BMI) =65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Disease of central nervous system Previous injury of central nervous system Disease affecting peripheral nervous system, or medication affecting peripheral nervous system
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To find the incidence of reappearance of nondepolarizing neuromuscular block after reversal with neostigmine.;Secondary Objective: Possible side-effects;Primary end point(s): Incidence of reappearence of nondepolarizing neuromuscular block after reversal with neostigmine.;Timepoint(s) of evaluation of this end point: Lenght of postanaesthesia care | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): none;Timepoint(s) of evaluation of this end point: none | — |
Countries
Finland
Contacts
Public ContactTampere University Hospital
Tampere University Hospital
Outcome results
None listed